E. Dokoupilová

发表

Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study

U. Müller-Ladner, S. Visvanathan, Patrick Baum, 2019, Annals of the rheumatic diseases.

Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study

Ines Brueckmann, P. Wiland, N. Gaylis, 2020, BioDrugs.

A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy

J. Choe, J. Smolen, A. Baranauskaitė, 2015, Annals of the rheumatic diseases.

Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis

R. Fleischmann, Wuyan Zhang, E. Dokoupilová, 2022, Rheumatology and Therapy.

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial

F. Ariel, P. Rahman, E. Lee, 2019, The Lancet.

Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial

Jacques P. Brown, H. Genant, A. Grauer, 2017, The Lancet.

FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension

M. Genovese, W. Porawska, H. Kellner, 2019, Arthritis Research & Therapy.

Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3‐Year Results from the Phase 3 MEASURE 3 Study

K. Pavelka, A. Kivitz, A. Stefańska, 2020, ACR open rheumatology.

Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3

K. Pavelka, A. Kivitz, H. Tahir, 2017, Arthritis Research & Therapy.

Secukinumab after anti-tumour necrosis factor-α therapy: a phase III study in active rheumatoid arthritis

P. Sfikakis, T. Takeuchi, H. Richards, 2018, Scandinavian journal of rheumatology.

OP0223 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-PSA-2): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL

W. Tillett, M. Genovese, P. Mease, 2020, Annals of the Rheumatic Diseases.

One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study

M. Genovese, P. Durez, Sang-Heon Lee, 2014, The Journal of Rheumatology.

Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study

J. Choe, J. Smolen, W. Porawska, 2017, Annals of the rheumatic diseases.

Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2)

A. Orbai, J. Birt, B. Combe, 2020, Rheumatology and Therapy.

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

U. Wagner, A. Gottlieb, A. Orbai, 2017, The Lancet.

Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2

W. Tillett, P. Mease, K. Papp, 2020, Annals of the Rheumatic Diseases.

Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)

P. Rahman, P. Mease, I. McInnes, 2018, Arthritis Research & Therapy.

Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study

Patrick Durez, M. Genovese, V. Mazurov, 2012, Annals of the rheumatic diseases.

Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo‐Controlled Phase III Study

A. Deodhar, J. Braun, A. Kivitz, 2020, Arthritis & Rheumatology (Hoboken, N.j.).

Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo‐Controlled Phase III Study

A. Deodhar, J. Braun, A. Kivitz, 2020, Arthritis & rheumatology.

Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double‐Blind, Active Comparator– and Placebo‐Controlled Study

F. Blanco, C. Codding, H. Richards, 2017, Arthritis & rheumatology.

Efficacy and Safety of Anti–Interleukin‐20 Monoclonal Antibody in Patients With Rheumatoid Arthritis: A Randomized Phase IIa Trial

P. Leszczyński, J. Cañete, L. Šenolt, 2015, Arthritis & rheumatology.

Efficacy and safety of secukinumab in patients with spondyloarthritis and enthesitis at the Achilles tendon: results from a phase 3b trial

E. de Miguel, X. Baraliakos, F. Behrens, 2021, Rheumatology.

Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study

W. Tillett, P. Mease, K. Papp, 2021, Rheumatology and Therapy.

Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study

U. Wagner, Z. Tallóczy, A. Kivitz, 2018, Rheumatology and Therapy.

Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis

M. Weinblatt, A. Baranauskaitė, J. Ghil, 2018, Arthritis & rheumatology.

Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis

M. Weinblatt, J. Vencovský, J. Choe, 2017, Arthritis & rheumatology.

J. Choe, J. Smolen, A. Baranauskaitė, 2017, Rheumatology.

FRI0162 Comparable Safety and Immunogenicity and Sustained Efficacy after Transition To SB2 (An Infliximab Biosimilar) vs Ongoing Infliximab Reference Product in Patients with Rheumatoid Arthritis: Results of Phase III Transition Study

J. Choe, J. Smolen, A. Baranauskaitė, 2016 .

Efficacy and safety of etanercept in psoriasis and psoriatic arthritis in the PRESTA study: analysis in patients from Central and Eastern Europe

L. Kemény, M. Majdan, P. Vítek, 2018, The Journal of dermatological treatment.

Clinical effectiveness and safety of intra-articular injection of HYALGO in the management of knee osteoarthritis symptoms: A multicenter prospective study.

K. Pavelka, E. Dokoupilová, N. Giordan, 2021, Journal of clinical orthopaedics and trauma.

OP0258 IZOKIBEP (ABY-035) IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS – 16-WEEK RESULTS FROM A PHASE 2 STUDY

N. Brun, K. de Vlam, F. Behrens, 2022, Annals of the Rheumatic Diseases.

An international, multicentre, double-blind, randomized study (DISSCO): effect of diacerein vs celecoxib on symptoms in knee osteoarthritis.

J. Raynauld, J. Pelletier, J. Martel-Pelletier, 2020, Rheumatology.

FRI0161 Sustained Efficacy and Comparable Safety and Immunogenicity after Transition To SB5 (An Adalimumab Biosimilar) vs Continuation of The Adalimumab Reference Product in Patients with Rheumatoid Arthritis: Result of Phase III Study

V. Zhdan, M. Weinblatt, J. Jaworski, 2016 .

OP0100 Superior Gains in Bone Mineral Density and Estimated Strength at The Hip for Romosozumab Compared with Teriparatide in Women with Postmenopausal Osteoporosis Transitioning from Bisphosphonate Therapy: Results of The Phase 3 Open-Label Structure Study

A. Grauer, T. Keaveny, K. Engelke, 2016 .

Superior Gains in Bone Mineral Density (BMD) and Estimated Strength at the Hip for Romosozumab Compared With Teriparatide (TPTD) in Women With Postmenopausal Osteoporosis Transitioning From Bisphosphonate Therapy: Results of the Phase 3 Open-label STRUCTURE Study

Jacques P. Brown, H. Genant, T. Keaveny, 2016 .

FRI0087 EFFICACY, SAFETY, AND IMMUNOGENICITY RESULTS OF THE SWITCH FROM REFERENCE ADALIMUMAB (REFADL) TO SANDOZ BIOSIMILAR ADALIMUMAB (GP2017, SDZ-ADL) FROM ADMYRA PHASE 3 STUDY IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS (RA)

P. Wiland, N. Gaylis, S. Jeka, 2019, Poster Presentations.

Intraarticular Injection of a Cross-Linked Sodium Hyaluronate Combined with Triamcinolone Hexacetonide (Cingal) to Provide Symptomatic Relief of Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo-Controlled Multicenter Clinical Trial

G. Vásárhelyi, M. Szendrői, L. Hangody, 2017, Cartilage.

Dose-response of hyaluronate-based viscoelastic hydrogels for the treatment of knee osteoarthrosis: a prospective, randomized, comparative clinical trial

K. Pavelka, V. Santilli, A. Bernetti, 2020 .

Evaluation of the efficacy and safety of terguride in patients with fibromyalgia syndrome: results of a twelve-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

E. Dokoupilová, Markus Gaubitz, Oliver Distler, 2010, Arthritis and rheumatism.

U. Müller-Ladner, S. Visvanathan, H. Kellner, 2019, Annals of the rheumatic diseases.

Effect of treatment with original or biosimilar adalimumab on SARS-CoV2 vaccination antibody titers

D. Vetchý, E. Dokoupilová, Sylvie Pavloková, 2024, International journal of pharmaceutics: X.